Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Metagenomi Therapeutics, Inc. (MGX)

Metagenomi Therapeutics furnishes September 2026 corporate presentation

Neutral Impact 2 of 5 other Written later

Metagenomi Therapeutics filed a Form 8-K furnishing its September 2026 corporate presentation as Exhibit 99.1 under Regulation FD. The presentation restates the company's cash position of $120.7 million at the end of Q2 2026, its runway through Q4 2027, and its timeline for MGX-001, its lead hemophilia A program.

Key points

  • Cash, cash equivalents and available-for-sale marketable securities were $120.7 million at end of Q2 2026, with runway anticipated through Q4 2027.
  • MGX-001 IND submission is planned for Q4 2026, with first patient dosing planned for 2027.
  • Preclinical data cited include 623 potential off-target sites tested, with no off-target edits identified in primary human hepatocytes at any dose.

The filing

CompanyMetagenomi Therapeutics, Inc. (MGX)
Form8-K, current report
Filed with the SECSep 21, 2026, 8:49 PM ET
Accession number0001193125-26-397037

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 21, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.